Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-14 3:11 pm Sale |
2022-12-31 | 13G | Monte Rosa Therapeutics, Inc. GLUE |
Cormorant Asset Management LP | 2,893,717 5.980% |
-108,483 (-3.61%) |
Filing History |
| 2023-02-14 12:38 pm Sale |
2022-12-31 | 13G | Monte Rosa Therapeutics, Inc. GLUE |
PRICE T ROWE ASSOCIATES INC | 3,683,430 7.600% |
-1,175,197 (-24.19%) |
Filing History |
| 2023-02-14 09:40 am Purchase |
2022-12-31 | 13G | Monte Rosa Therapeutics, Inc. GLUE |
AVORO CAPITAL ADVISORS LLC | 4,325,000 8.900% |
1,013,566 (+30.61%) |
Filing History |
| 2023-02-09 12:01 pm Sale |
2023-02-09 | 13G | Monte Rosa Therapeutics, Inc. GLUE |
FMR CORP | 6,217,458 12.846% |
-758,429 (-10.87%) |
Filing History |
| 2023-02-03 4:27 pm Purchase |
2022-12-31 | 13G | Monte Rosa Therapeutics, Inc. GLUE |
BLACKROCK INC BLK |
3,598,536 7.400% |
2,006,738 (+126.07%) |
Filing History |
| 2022-02-14 3:08 pm Sale |
2021-12-31 | 13G | Monte Rosa Therapeutics, Inc. GLUE |
Cormorant Asset Management LP | 3,002,200 6.460% |
-191,774 (-6.00%) |
Filing History |
| 2022-02-11 10:06 am Purchase |
2021-12-31 | 13G | Monte Rosa Therapeutics, Inc. GLUE |
AVORO CAPITAL ADVISORS LLC | 3,311,434 7.100% |
3,311,434 (New Position) |
Filing History |
| 2022-02-10 1:16 pm Purchase |
2022-01-31 | 13G | Monte Rosa Therapeutics, Inc. GLUE |
PRICE T ROWE ASSOCIATES INC | 4,858,627 10.400% |
711,708 (+17.16%) |
Filing History |
| 2022-02-10 1:13 pm Purchase |
2021-12-31 | 13G | Monte Rosa Therapeutics, Inc. GLUE |
PRICE T ROWE ASSOCIATES INC | 4,146,919 8.900% |
4,146,919 (New Position) |
Filing History |
| 2022-02-09 5:22 pm Sale |
2022-01-31 | 13G | Monte Rosa Therapeutics, Inc. GLUE |
BLACKROCK INC BLK |
1,591,798 3.400% |
-761,966 (-32.37%) |
Filing History |
| 2022-02-09 09:22 am Purchase |
2022-02-08 | 13G | Monte Rosa Therapeutics, Inc. GLUE |
FMR CORP | 6,975,887 14.999% |
803,610 (+13.02%) |
Filing History |
| 2022-02-04 4:12 pm Purchase |
2021-12-31 | 13G | Monte Rosa Therapeutics, Inc. GLUE |
BLACKROCK INC BLK |
2,353,764 5.100% |
2,353,764 (New Position) |
Filing History |
| 2021-08-10 10:33 am Purchase |
2021-08-09 | 13G | Monte Rosa Therapeutics, Inc. GLUE |
FMR CORP | 6,172,277 13.873% |
6,172,277 (New Position) |
Filing History |
| 2021-07-12 3:49 pm Purchase |
2021-06-28 | 13D | Monte Rosa Therapeutics, Inc. GLUE |
New Enterprise Associates 17, L.P. | 7,694,916 17.300% |
7,694,916 (New Position) |
Filing History |
| 2021-07-08 4:31 pm Purchase |
2021-06-28 | 13D | Monte Rosa Therapeutics, Inc. GLUE |
Versant Venture Capital VI, L.P. | 6,799,115 15.300% |
6,799,115 (New Position) |
Filing History |
| 2021-07-08 4:02 pm Purchase |
2021-06-28 | 13G | Monte Rosa Therapeutics, Inc. GLUE |
Cormorant Asset Management LP | 3,193,974 7.180% |
3,193,974 (New Position) |
Filing History |